EUVIMEDEUVIMED entdecken
Crossref

Leucovorin for Cerebral Folate Deficiency

The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · 75-77

DOI: 10.58347/tml.2026.1754b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved use of oral leucovorin calcium (folinic acid) for treatment of cerebral folate transport deficiency in patients who have a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD). It is the first drug to be approved for this extremely rare disorder.

Schlagwörter

Stichwörter der Autor:innen

adverse effectsautismcerebral folate deficiencydosagedrug interactionsefficacyleucovorinsafety

Zitieren

APA

(2026). Leucovorin for Cerebral Folate Deficiency. The Medical Letter on Drugs and Therapeutics, 68(1754), 75-77. https://doi.org/10.58347/tml.2026.1754b

Vancouver

Leucovorin for Cerebral Folate Deficiency. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):75-77. doi:10.58347/tml.2026.1754b

BibTeX
@article{euvimed2026,
  title = {Leucovorin for Cerebral Folate Deficiency},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1754},
  pages = {75--77},
  doi = {10.58347/tml.2026.1754b}
}
Kostenlos starten →